Table 1. Characteristics of individuals stratified by tertiles of Apo B/A1 ratio decrease.
| Variables | Total patients (n = 448) | Tertile 1 of Apo B/A1 ratio decrease ≤0.146 (n = 149) | Tertile 2 of Apo B/A1 ratio decrease 0.146–0.346 (n = 150) | Tertile 3 of Apo B/A1 ratio decrease >0.346 (n = 149) | p-value |
|---|---|---|---|---|---|
| Clinical characteristics | |||||
| Age, years | 63.5 ± 10.7 | 64.4 ± 10.4 | 63.7 ± 10.3 | 62.4 ± 11.3 | 0.238 |
| Male | 325 (72.4) | 101 (67.8) | 103 (68.7) | 121 (81.2) | 0.015 |
| Diabetes | 220 (49.0) | 77 (51.7) | 74 (49.3) | 69 (46.3) | 0.649 |
| Hypertension | 242 (53.9) | 95 (63.8) | 77 (51.3) | 70 (47.0) | 0.011 |
| Smoking | 199 (44.3) | 69 (46.3) | 57 (38.0) | 73 (49.0) | 0.137 |
| MI at index PCI | 261 (58.1) | 83 (55.7) | 84 (56.0) | 94 (63.1) | 0.343 |
| eGFR, (ml/min/1.73 m2) | 85.2 ± 19.1 | 84.8 ± 19.4 | 84.2 ± 19.7 | 86.6 ± 18.2 | 0.523 |
| BMI (kg/m2) | 23.6 ± 3.15 | 23.6 ± 3.57 | 23.7 ± 3.05 | 23.6 ± 2.81 | 0.886 |
| EF (%) | 56.1 ± 11.3 | 56.1 ± 11.4 | 56.2 ± 11.7 | 56.0 ± 10.8 | 0.989 |
| Beta blocker | 386 (86.0) | 125 (83.9) | 128 (85.3) | 133 (89.3) | 0.381 |
| ACEi or ARB | 390 (86.9) | 128 (85.9) | 128 (85.3) | 134 (89.9) | 0.435 |
| CCB | 66 (14.7) | 24 (16.1) | 22 (14.7) | 20 (13.4) | 0.807 |
| High intensity statin at index PCI | 229 (51.0) | 60 (40.3) | 71 (47.3) | 98 (65.8) | <0.001 |
| High intensity statin at lipid follow-up | 190 (42.4) | 53 (35.6) | 57 (38.0) | 80 (53.7) | 0.003 |
| Procedural characteristics | |||||
| Multi vessel disease | 218 (48.6) | 77 (51.7) | 71 (47.3) | 70 (47.0) | 0.665 |
| Type b2/c lesions | 230 (51.2) | 71 (47.7) | 86 (57.3) | 73 (49.0) | 0.192 |
| PCI on LAD lesion | 301 (67.0) | 92 (61.7) | 109 (72.7) | 100 (67.1) | 0.132 |
| Lipid profile at index PCI | |||||
| TC (mg/dL) | 169.8 ± 35.9 | 151.4 ± 32.4 | 171.1 ± 33.6 | 186.8 ± 32.9 | <0.001 |
| TG (mg/dL) | 157.0 ± 117.1 | 153.4 ± 125.8 | 159.3 ± 124.0 | 158.4 ± 100.7 | 0.898 |
| HDL-C (mg/dL) | 43.9 ± 12.1 | 47.1 ± 14.3 | 44.9 ± 11.5 | 39.6 ± 8.75 | <0.001 |
| LDL-C (mg/dL) | 103.0 ± 31.9 | 82.0 ± 24.1 | 102.5 ± 28.5 | 124.6 ± 27.7 | <0.001 |
| Lp(a) (mg/dL) | 25.5 ± 26.7 | 27.1 ± 28.9 | 24.6 ± 26.0 | 25.0 ± 25.3 | 0.681 |
| Apo B (mg/dL) | 88.2 ± 23.6 | 70.9 ± 17.8 | 85.7 ± 17.4 | 107.9 ± 19.0 | <0.001 |
| Apo A1 (mg/dL) | 124.1 ± 26.5 | 132.9 ± 28.0 | 127.7 ± 26.4 | 111.8 ± 19.5 | <0.001 |
| Apo B/A1 ratio | 0.740 ± 0.249 | 0.549 ± 0.155 | 0.685 ± 0.138 | 0.985 ± 0.209 | <0.001 |
| Lipid profile at follow-up | |||||
| TC (mg/dL) | 113.5 ± 18.0 | 115.0 ± 19.6 | 114.0 ± 18.7 | 111.5 ± 15.4 | 0.231 |
| TG (mg/dL) | 113.6 ± 73.4 | 123.3 ± 86.3 | 110.6 ± 68.3 | 107.1 ± 63.1 | 0.134 |
| HDL-C (mg/dL) | 44.7 ± 13.1 | 42.6 ± 14.7 | 46.5 ± 13.0 | 44.9 ± 11.1 | 0.036 |
| LDL-C (mg/dL) | 56.0 ± 10.6 | 57.1 ± 9.5 | 55.6 ± 11.3 | 55.4 ± 10.9 | 0.295 |
| Lp(a) (mg/dL) | 25.7 ± 26.8 | 28.0 ± 26.8 | 25.2 ± 26.5 | 23.9 ± 27.2 | 0.406 |
| Apo B (mg/dL) | 57.9 ± 12.2 | 60.6 ± 12.6 | 56.3 ± 12.8 | 56.8 ± 10.7 | 0.003 |
| Apo A1 (mg/dL) | 125.8 ± 27.0 | 120.4 ± 29.6 | 130.9 ± 25.6 | 125.9 ± 24.6 | 0.003 |
| Apo B/A1 ratio | 0.485 ± 0.166 | 0.543 ± 0.217 | 0.447 ± 0.135 | 0.465 ± 0.113 | <0.001 |
Data are given as mean ± SD, or as number (%). ACEi; angiotensin converting enzyme inhibitor, Apo A1; apolipoprotein A1, Apo B; apolipoprotein B, ARB; angiotensin receptor blocker, BMI; body mass index, CCB; calcium channel blocker, DES; drug-eluting stent, EF; ejection fraction, eGFR; estimated glomerular filtration rate, HDL-C; high-density lipoprotein cholesterol, LAD; left anterior descending artery, LDL-C; low-density lipoprotein cholesterol, Lp(a); lipoprotein (a), PCI; percutaneous coronary intervention, TC; total cholesterol, TG; triglyceride.